The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis
- PMID: 35570260
- DOI: 10.1186/s43046-022-00123-6
The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis
Abstract
Background: Multiple myeloma (MM) predominantly affects older patients; many of whom do not undergo autologous hematopoietic stem cell transplant (AHSCT) despite the associated survival benefits. This study was conceived to investigate the patterns of AHSCT among MM patients with due regard to their age and standardized fitness assessments.
Methods: Fitness scores as per the hematopoietic stem cell transplant-comorbidity index (HSCT-CI) and risk scores as per the revised-myeloma comorbidity index (R-MCI) of MM patients treated between January 2017 and December 2019 were analyzed to assess fitness for AHSCT. Proportions of patients who underwent AHSCT were calculated with regard to age and fitness for AHSCT.
Results: Of the 81 eligible patient records with a median age of 62 years, the HSCT-CI classified 79.6% and 77.8% of patients aged ≤65 years and >65 years as AHSCT eligible (p 1). Using the R-MCI, 96.3% and 81.5% of patients aged ≤65 years and >65 years, respectively, were classified as eligible for AHSCT (p 0.0381). Overall, patients aged ≤65 years underwent AHSCT with a greater frequency compared to those aged >65years (38.9 vs. 14.8%, p 0.0402). Irrespective of the age group, there was a statistically significant difference (p 0.0167) in terms of survival which favored those who underwent AHSCT.
Conclusions: Both the HSCT-CI and the R-MCI revealed that nearly 80% of patients aged >65 years were fit enough to receive AHSCT. However, far fewer patients of this age group underwent AHSCT. We propose that the routine inclusion of objective fitness assessment could ensure that fit older patients undergo AHSCT and thus do not miss out on the benefits of the same.
Keywords: Age and fitness; Autologous hematopoietic transplant in older patients; Autologous transplant; Geriatric myeloma; Multiple myeloma fitness assessment.
© 2022. The Author(s).
Similar articles
-
Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma.J Natl Cancer Inst. 2019 Jan 1;111(1):78-85. doi: 10.1093/jnci/djy073. J Natl Cancer Inst. 2019. PMID: 29897481 Free PMC article.
-
Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease.Leuk Res. 2019 Apr;79:75-80. doi: 10.1016/j.leukres.2019.01.002. Epub 2019 Jan 6. Leuk Res. 2019. PMID: 30654975
-
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.Blood Cancer J. 2021 Jan 7;11(1):5. doi: 10.1038/s41408-020-00400-4. Blood Cancer J. 2021. PMID: 33414400 Free PMC article.
-
Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: an overview for nurses in community practice.Clin J Oncol Nurs. 2013 Dec;17 Suppl:13-24. doi: 10.1188/13.CJON.S2.13-24. Clin J Oncol Nurs. 2013. PMID: 24280455 Review.
-
Allogeneic hematopoietic cell transplantation for multiple myeloma.Biomed Pharmacother. 2002 May;56(3):133-8. doi: 10.1016/s0753-3322(02)00175-0. Biomed Pharmacother. 2002. PMID: 12046684 Review.
Cited by
-
Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India.Appl Health Econ Health Policy. 2024 Jul;22(4):569-582. doi: 10.1007/s40258-024-00877-1. Epub 2024 Mar 7. Appl Health Econ Health Policy. 2024. PMID: 38448720
-
Long-Term Outcomes of Autologous Hematopoietic Stem Cell Transplant (HSCT) for Multiple Myeloma: While New Horizons Emerge, It Is Still Only a Silver Lining for Resource-Constrained Settings.Cureus. 2023 Mar 24;15(3):e36642. doi: 10.7759/cureus.36642. eCollection 2023 Mar. Cureus. 2023. PMID: 37155458 Free PMC article.
References
-
- Auner HW, Garderet L, Kröger N. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. Br J Haematol. 2015;171(4):453–62. - DOI
-
- Rosenberg AS, Brunson A, Jonas BA, Keegan THM, Wun T. Association between autologous stem cell transplant and survival among californians with multiple myeloma. J Natl Cancer Inst. 2019;111(1). [cited 2020 Oct 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/29897481/ .
-
- Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997;20(6):445–50. [cited 2020 Oct 7] Available from: https://pubmed.ncbi.nlm.nih.gov/9313876/
-
- Clemmons AB, Anderegg S. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: a cost-saving initiative in a resource constrained environment. J Oncol Pharm Pract. 2017;23(5):384–8. [cited 2020 Oct 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/27000280/ .
-
- Rondelli D, Kun TL, Mathews V, Gooneratne LV, Tuladhar S, Neupane S, et al. First Global Blood & Marrow Transplant [GlobalBMT] Conference in Kathmandu with experiences from Nepal, India, Singapore and Sri Lanka. J Glob Health. 2018;8(1):1–5. - DOI
MeSH terms
LinkOut - more resources
Medical